GleamWall
中文EN

EVAX Evaxion A/S IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1828253 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY125.1%
TTM net income YoY27.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-122.7%
Net margin-102.4%
FCF margin-88.2%
EBITDA margin—

Returns

ROE-100.2%
ROA-37.7%
ROIC (approx.)—
Asset turnover0.37x

Leverage & solvency

Liabilities / assets40.0%
Debt / equity0.32x
Current ratio5.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$7.53M$3.34M
R&D expense$9.97M$10.46M
SG&A expense$6.79M$7.62M
Operating income-$9.23M-$14.73M
Interest expense$0$0
Pretax income-$8.62M-$11.36M
Income tax-$908,000-$788,000
Net income-$7.71M-$10.57M
EPS (basic)-0.02-0.20
EPS (diluted)——
Balance sheet
Cash & equivalents$23.23M$5.95M
Current assets$24.90M$8.77M
PP&E, netmay include right-of-use assets (IFRS)$3.32M$3.51M
Intangibles$0$0
Total assets$28.41M$12.48M
Current liabilities$4.26M$4.37M
Short-term debt$190,000$159,000
Long-term debt$5.35M$8.01M
Total debt$5.54M$8.17M
Total liabilities$11.37M$14.14M
Shareholders' equity$17.04M-$1.65M
Net debt-$17.70M$2.21M
Shares outstanding417.01M—
Cash flow statement
Operating cash flow-$6.62M-$12.94M
Capital expenditure$11,000$0
Free cash flow-$6.64M-$12.94M
Investing cash flow-$14,000-$3,000
Financing cash flow$22.41M$13.13M
Stock-based compensation$307,000$357,000

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.